LDL as necessary initiator
The argument
Because apoB-lipoproteins initiate and drive atherosclerosis and lowering LDL reduces events in proportion to the reduction achieved, atherosclerosis is fundamentally an LDL-dependent process, so inflammation and insulin resistance act as amplifiers of that process rather than primary drivers independent of LDL.
Does it work?
- Does it follow?
- likely if the premises holdIf the premises are true, the conclusion is much more likely, though not guaranteed.constitution →
- Do the premises hold?
- 1 verified1 not separately assessed
Granting its premises, the argument makes it much more likely that atherosclerosis depends on LDL, and so that other factors are not drivers independent of it. It does not guarantee this, because a factor can still be a major amplifier. The argument rests on proportional event reduction with LDL lowering, which is assessed as verified, and on apoB-lipoproteins initiating and driving atherosclerosis, which is not yet assessed but is backed by convergent Mendelian randomization and trial evidence.
Premises
- UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →LDL particles accumulating in the arterial wall initiate and drive atherosclerosis
- VerifiedThe evidence, examined directly, establishes the claim.constitution →Randomized trials show lowering LDL cholesterol reduces cardiovascular events proportionally to the reduction achieved
Where it is made
Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.
No source is recorded as making it.
Earlier ratings
- Aug 7, 2026
The inference goes through, and it carries the verdict. Given apoB-lipoproteins as the necessary initiator of atherosclerosis and the proportional reduction of events with LDL lowering, atherosclerosis is fundamentally LDL-dependent, so inflammation and insulin resistance cannot be primary drivers independent of LDL. The argument stands on the causal-necessity premise, which is strongly supported by convergent genetic and randomized-trial evidence and remains uncontested in the current literature.
- Aug 7, 2026
The inference goes through, and it carries the verdict. Given apoB-lipoproteins as the necessary initiator of atherosclerosis and the proportional reduction of events with LDL lowering, atherosclerosis is fundamentally LDL-dependent, so inflammation and insulin resistance cannot be primary drivers independent of LDL. The argument stands on the causal-necessity premise, which is strongly supported by convergent genetic and randomized-trial evidence.